1-4 of 4
Zachary A. Knight
Close
Sort by
Journal Articles

Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell–mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach

Matthias Niedermeier, Bryan T. Hennessy, Zachary A. Knight, Marina Henneberg, Jianhua Hu, Antonina V. Kurtova, William G. Wierda, Michael J. Keating, Kevan M. Shokat, Jan A. Burger
Journal: Blood
Blood (2009) 113 (22): 5549–5557.
https://doi.org/10.1182/blood-2008-06-165068
Published: 2009
Includes: Supplemental data
Journal Articles

PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.

Sophie Park, MD, Nicolas Chapuis, MD, Valerie Bardet, PhD, Lise Willems, MD, Jerome Tamburini, MD, Zachary A. Knight, PhD, Kevan M. Shokat, PhD, Nabih Azar, MD, Norbert Ifrah, MD, PhD, Francois Dreyfus, MD, PhD, Patrick Mayeux, MD, Catherine Lacombe, MD, PhD, Didier Bouscary, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 876.
https://doi.org/10.1182/blood.V110.11.876.876
Published: 2007
Journal Articles

Knock-outs and inhibitors: one and the same?

Zachary A. Knight, Kevan M. Shokat
Journal: Blood
Blood (2006) 107 (2): 420–421.
https://doi.org/10.1182/blood-2005-10-4264
Published: 2006
Journal Articles

Another possible mechanism of resistance to STI571

Zachary A. Knight
Journal: Blood
Blood (2000) 96 (12): 4003–4005.
https://doi.org/10.1182/blood.V96.12.4003
Published: 2000